一种丁二酸衍生物或3-芳基丙酸的合成方法转让专利
申请号 : CN201911022392.0
文献号 : CN111777477B
文献日 : 2021-09-14
发明人 : 余达刚 , 李静 , 黄河 , 叶剑衡 , 冉川昆 , 苗萌 , 王伟 , 陈瀚蛟 , 周文俊 , 于博
申请人 : 四川大学
摘要 :
权利要求 :
1.一种丁二酸衍生物或3‑芳基丙酸的合成方法,其特征在于,包括如下步骤:S1:将碱加入反应装置中,再在CO2的气氛下加入溶剂、反应底物、硫酚和添加剂,经脱气后得反应液;所述碱为叔丁醇钠或碳酸钾;所述溶剂为NMP或DMSO;所述硫酚为4‑叔丁基苯硫酚;所述添加剂为叔丁醇或异丙醇;
S2:向装有反应液的反应装置中充入CO2气体,至反应装置内部压力为0.1Mpa;
S3:将反应液置于距可见光光源1 cm处,在室温下搅拌反应24 h,然后用淬灭剂淬灭反应,旋干溶剂得初产物;所述淬灭剂包括3体积份的乙酸乙酯和1.5体积份的盐酸或硫酸;
S4:通过快速柱层析纯化初产物,得丁二酸衍生物或3‑芳基丙酸;
所述反应底物为丙烯酸酯类化合物或芳基乙烯类化合物;所述丙烯酸酯类化合物的结构式如式(III)所示,
,
1 2 3 4
R和R为氢或烷基,R为烷基、烯基或芳香基,R为如下基团中的一种,;
所述芳基乙烯类化合物的结构式如式(IV)所示,,
5 6
Ar为芳香基或杂芳基,R为芳香基或烷基,R为氢或烷基。
2.根据权利要求1所述的丁二酸衍生物或3‑芳基丙酸的合成方法,其特征在于:所述碱的添加量为反应底物的2.5 3.0倍当量;所述硫酚的添加量为反应底物的2 3倍当量;所述~ ~
添加剂的添加量为反应底物的1 3倍当量。
~
3.根据权利要求1所述的丁二酸衍生物或3‑芳基丙酸的合成方法,其特征在于,S1中反应液脱气的具体方法为:将装有反应液的反应装置置于液氮下,待完全冰冻后,抽气5 min;
待完全解冻后再置于液氮下冷冻,完全冰冻后,抽气5 min,完成脱气。
4.根据权利要求1所述的丁二酸衍生物或3‑芳基丙酸的合成方法,其特征在于:所述可见光光源为30W的蓝色LED灯。
5.根据权利要求1所述的丁二酸衍生物或3‑芳基丙酸的合成方法,其特征在于,S4中层析柱纯化所用洗脱液为石油醚、乙酸乙酯和冰醋酸的混合物,混合物中石油醚与乙酸乙酯的体积比为10:1,冰醋酸的质量分数为0.4 0.5%。
~
说明书 :
一种丁二酸衍生物或3‑芳基丙酸的合成方法
技术领域
背景技术
酸;四是利用乙炔与一氧化碳及水在钴催化剂存在下,于酸性介质中反应产生丁二酸;五是
电解法氧化顺丁烯二酸或顺酐;六是生物发酵法。上述六种方法中,除了生物发酵法和电解法
之外,其余方法都需要使用贵金属催化剂和高温,条件苛刻;另外,丙烯酸羰基合成法尚未得
到工业应用;电解法采用铅板为电极,容易造成重金属残留和污染,对电解设备要求也较高。
催化的方法与甲酸反应。上述方法中,催化加氢和芳基乙烯的羧化需要高压,对反应设备要
求较高,并且需要昂贵的催化剂才能实现;铬酸盐氧化丙苯的方法存在氧化剂的浪费和过
度氧化等问题;通过苄基丙二酸二乙酯合成3‑芳基丙酸操作繁琐,原子经济性不高;而芳基
乙烯的羧化反应往往伴随着α‑羧基化的副产物产生。
合理利用的基础性研究,通过化学手段利用CO2制备重要有机化合物是一种非常重要的途
径。如果能够实现其向具有重要价值的羧酸分子的高效转化,并实现其工业化大规模生产,
不仅可以创造化工生产工业模式,降低生产成本,还将大大提高CO2资源的利用效率,为解决
温室效应提供一种新的思路。目前化学家们已经实现了一些二氧化碳的转化并且获得的一系
列具有高附加值化学品。然而,对二氧化碳的化学利用特别是实现其工业化的部分仅仅是冰
山一角,其主要原因归结于二氧化碳的动力学稳定性和热力学惰性。因此,实现二氧化碳的化
学利用,必须从二氧化碳的活化入手。随着对二氧化碳活化研究的深入,化学家们发展了一些
不同的二氧化碳活化模式来促进二氧化碳的利用,如金属催化活化、路易斯酸碱协同活化、光
电活化和生物酶催化活化等等,将这些活化模式应用于二氧化碳参与的反应中去,探索新的
二氧化碳转化反应,推动二氧化碳的资源化利用进程,这具有重要的学术价值和实际意义。
发明内容
的合成方法包括如下步骤:
基,R为氢或烷基。
外,该体系也很难避免硫羧基化的副反应。为了避免上述问题,本发明的合成方法中利用
CO2参与丙烯酸酯或芳基乙烯的羧化,具有较强的选择性,可在指定的位置形成羧基。
表1所示,表中标准反应条件为:1a(0.2mmol),硫酚(0.4mmol),碱(0.5mmol),溶剂(2mL),
1atm CO2,30W蓝光照射,室温,24小时。N.D.为未检测到产物。
一系列的控制反应表明,硫酚、碱、可见光和二氧化碳对于这种转化都是必不可少的。如果
不添加叔丁醇,产物2a的产率会明显降低。添加4‑叔丁基苯硫酚时产率可达64%。
较好的产率得到目标产物3‑芳基丙酸4,3‑芳基丙酸的合成反应式如式(II)所示,
体现出了很好的化学选择性,O‑烯丙基取代的底物(3k)也能顺利地与CO2发生反应,且以较
高的产率得到相应的产物。此外,在碱性条件下,苄醇取代的底物(3x)也能顺利的得到目标
产物。α芳基取代和烷基取代的底物也显示出较好的反应性。最重要的是,抗糖尿病的GPR40
活性药物(4ga)也能通过本发明中的方法进行高效的合成。结果进一步展示了本发明方法
具有很好的应用前景。另外,三取代的芳基乙烯(3ka)也是可以兼容我们的反应体系,得到
中等收率的目标产物。
进行,得到4a,产率78%。
产率也基本不受影响;本发明克服了现有技术试剂毒性高、反应条件苛刻的缺陷,所用原料
廉价易得,具有良好的工业应用前景。
具体实施方式
量分数为0.4~0.5%。
碱被使用,反应48h。各化合物下方的百分数为产率,如“2a”为化合物的编号。
位除了甲基1a之外,其他一级取代基团1k‑1o,二级取代基团1p‑1r,三级取代基团1s,以及
芳基取代1t‑1w也都能以较好的收率得到目标产物。值得一提的是,烯丙基取代的丙烯酸酯
1o表现出很好的化学选择性。此外,三取代的丙烯酸酯1x‑1ba,甚至是四取代的丙烯酸酯
1ca‑1da也能得到相应的目标产物。综上所述,在本发明的体系下,一些活性分子修饰的丙
烯酸酯都能很好地兼容。
13
8.0Hz,3H);C NMR(101MHz,CDCl3)δ178.21,174.34,80.66,37.47,36.46,27.81,16.87;MS
(ESI‑):187.09.
13
1.70–1.58(m,6H),1.52(s,3H),1.18(d,J=4.0Hz,3H);C NMR(101MHz,CDCl3)δ177.85,
174.68,90.35,39.01,38.89,37.59,36.51,24.03,23.71,16.98;HRMS(ESI‑):calcd for
C11H17O4‑[M‑H]‑213.1132,found 213.1134.
13
(d,J=4.0Hz,3H),0.87(t,J=8.0Hz,3H);C NMR(101MHz,CDCl3)δ176.92,174.43,83.25,
37.39,36.63,33.39,25.45,25.38,17.11,8.09;HRMS(ESI‑):calcd for C10H17O4‑[M‑H]‑
201.1132,found 201.1136.
13
6H),1.65(s,6H),1.19(d,J=8.0Hz,3H);C NMR(101MHz,CDCl3)δ177.78,174.44,80.78,
41.14,37.81,36.75,36.15,30.79,17.06;HRMS(ESI‑):calcd for C15H21O4‑[M‑H]‑
265.1445,found 265.1444.
13
=16.0,4.0Hz,1H),1.43(d,J=12.0Hz,6H),1.17(d,J=8.0Hz,3H);C NMR(101MHz,
CDCl3)δ178.05,174.43,137.04,130.58,127.88,126.45,82.58,46.48,37.37,36.57,
25.87,25.75,16.98;HRMS(ESI‑):calcd for C15H19O4‑[M‑H]‑263.1289,found 263.1290.
13
1.46(m,1H),1.43–1.27(m,5H),1.21(d,J=4.0Hz,3H);C NMR(101MHz,CDCl3)δ178.04,
174.51,72.81,37.38,35.81,31.31,25.31,23.48,16.94;HRMS(ESI‑):calcd for C11H17O4‑
[M‑H]‑213.1132,found 213.1133.
4.98(m,1H),2.90–2.73(m,2H),2.43(dd,J=16.0,4.0Hz,1H),1.23–1.20(m,9H);C NMR
(101MHz,CDCl3)δ177.35,174.65,68.09,37.31,35.81,21.62,16.92;HRMS(ESI‑):calcd
for C8H13O4‑[M‑H]‑173.0819,found 173.0823.
(2h):浅黄色液体;H NMR(400MHz,CDCl3)δ4.57–4.56(m,1H),2.89–2.71(m,2H),2.42(dd,J
=16.0,4.0Hz,1H),2.05–2.61(m,2H),1.90–1.79(m,2H),1.77–1.72(m,2H),1.67–1.62(m,
2H),1.42–1.36(m,1H),1.34–1.32(m,1H),1.26–1.24(m,2H),1.21(d,J=4.0Hz,3H),1.00–
13
0.86(m,2H);C NMR(101MHz,CDCl3)δ177.36,177.33,174.87,174.83,77.50,77.49,
47.23,46.02,45.99,42.86,39.51,38.93,38.80,37.28,37.26,35.72,31.97,31.61,
29.33,29.29,27.70,16.96,16.89;HRMS(ESI‑):calcd for C15H21O4‑[M‑H]‑265.1445,
found 265.1445.
13
1.23(d,J=8.0Hz,3H),0.90(d,J=8.0Hz,6H);C NMR(101MHz,CDCl3)δ178.05,175.10,
70.85,37.29,35.60,27.63,18.94,18.92,16.96;HRMS(ESI‑):calcd for C16H15O2S‑[M‑H]‑
187.0976,found 187.0982.
13
1.38–1.33(m,2H),1.28–1.27(m,5H),1.24(d,J=8.0Hz,3H),0.89–0.86(m,7H);C NMR
(101MHz,CDCl3)δ177.77,175.20,67.12,38.70,37.29,35.68,30.32,28.86,23.73,22.92,
16.99,14.00,10.91;HRMS(ESI‑):calcd for C13H23O4‑[M‑H]‑243.1602,found 243.1598.
13
3H);C NMR(101MHz,CDCl3)δ178.11,174.29,80.67,43.49,35.93,27.95,24.99,11.21;
HRMS(ESI‑):calcd for C10H17O4‑[M‑H]‑201.1132,found 201.1135.
13
8.0Hz,3H);C NMR(101MHz,CDCl3)δ178.21,174.11,80.73,41.81,35.88,31.55,28.92,
27.95,22.43,13.85;HRMS(ESI‑):calcd for C12H21O4‑[M‑H]‑229.1445,found 229.1445.
13
1.88(m,1H),1.82–1.75(m,1H),1.46(s,9H);C NMR(101MHz,CDCl3)δ177.66,174.19,
141.37,128.41,128.34,126.00,80.95,41.94,36.53,33.79,33.19,28.00;HRMS(ESI‑):
calcd for C16H21O4‑[M‑H]‑277.1445,found 277.1445.
13
16.0,4.0Hz,1H),1.37(s,9H);C NMR(101MHz,CDCl3)δ178.07,173.19,138.23,129.09,
128.44,126.60,81.05,43.61,37.69,35.08,27.84.MS(ESI‑):263.11.All analytical
2
data are consistent with those reported in the literature.
13
2.30–2.23(m,1H),1.42(s,9H);C NMR(101MHz,CDCl3)δ177.72,173.53,134.54,117.66,
80.99,41.60,35.98,35.42,27.97;HRMS(ESI‑):calcd for C11H17O4‑[M‑H]‑213.1132,
found 213.1133.
13
9H),0.94(q,J=12.0,4.0Hz,6H);C NMR(101MHz,CDCl3)δ177.50,173.47,80.80,48.04,
32.67,30.02,28.00,20.03,19.43;HRMS(ESI‑):calcd for C11H19O4‑[M‑H]‑215.1289,
found 215.1286.
13
2H)1.56–1.50(m,2H),1.43(s,9H),1.36–1.28(m,1H),1.22–1.17(m,1H);C NMR(101MHz,
CDCl3)δ178.40,173.90,80.66,46.99,42.34,35.46,30.44,30.34,27.95,25.04,24.88;
HRMS(ESI‑):calcd for C13H21O4‑[M‑H]‑241.1445,found241.1446.
(dd,J=16.0,4.0Hz,1H),1.86–1.76(m,1H),1.54–1.50(m,2H),1.47–1.45(m,2H),1.43(s,
13
9H);C NMR(101MHz,CDCl3)δ177.76,172.84,81.16,67.86,67.80,47.16,37.18,33.24,
30.29,30.04,27.98;HRMS(ESI‑):calcd for C13H21O5‑[M‑H]‑257.1394,found 257.1396.
2.80–2.73(m,1H),2.51–2.44(m,2H),1.44(s,9H),0.97(s,9H);C NMR(101MHz,CDCl3)δ
178.25,172.89,80.61,51.86,32.58,32.50,27.98,27.87;HRMS(ESI‑):calcd for
C12H21O4‑[M‑H]‑229.1445,found 229.1440.
13
16.0,4.0Hz,1H),1.38(s,9H);C NMR(101MHz,CDCl3)δ176.69,172.02,138.11,128.73,
127.60,127.40,81.31,48.08,37.66,27.81;MS(ESI‑):249.09.
13
12.0Hz,1H),2.63(dd,J=16.0,4.0Hz,1H),2.33(s,3H),1.38(s,9H);C NMR(101MHz,
CDCl3)δ177.68,172.04,137.09,135.00,129.45,127.45,81.22,47.55,37.71,27.84,
21.07;HRMS(ESI‑):calcd for C11H17O4‑[M‑H]‑263.1289,found 263.1287.
120℃;H NMR(400MHz,CDCl3)δ7.19(d,J=12.0Hz,2H),6.85(d,J=8.0Hz,2H),3.89(dd,J
=8.0,4.0Hz,1H),3.79(s,3H),3.14(dd,J=16.0,8.0Hz,1H),2.63(dd,J=16.0,4.0Hz,
13
1H),1.38(s,9H);C NMR(101MHz,CDCl3)δ177.21,172.11,158.85,130.06,128.63,
114.11,81.20,55.22,47.10,37.62,27.82;HRMS(ESI‑):calcd for C15H19O5‑[M‑H]‑
279.1238,found 279.1237.
;H NMR(400MHz,CDCl3)δ7.22(dd,J=8.0,4.0Hz,2H),6.99(t,J=8.0Hz,2H),3.92(dd,J=
8.0,4.0Hz,1H),3.08(dd,J=16.0,12.0Hz,1H),2.59(dd,J=16.0,8.0Hz,1H),1.36(s,
13
9H);C NMR(101MHz,CDCl3)δ177.22,172.11,162.04(d,J=246.4Hz),133.93(d,J=
3.0Hz),129.20(d,J=8.1Hz),115.58(d,J=22.2Hz),81.46,47.45,38.02,27.76;19F NMR
(376MHz,CDCl3)δ‑115.17;HRMS(ESI‑):calcd for C14H16FO4‑[M‑H]‑267.1038,
found267.1040.
δ2.74–2.67(m,2H),1.44(s,7.5H),1.43(s,1.5H),1.20–1.16(m,6H);C NMR(101MHz,
CDCl3)δ180.08,173.95,81.07,42.98,42.32,27.92,14.77,14.10;HRMS(ESI‑):calcd for
C10H17O4‑[M‑H]‑201.1132,found 201.1133.
13
1.15(d,J=8.0Hz,3H),0.95–0.91(m,3H);C NMR(101MHz,CDCl3)δ180.54,179.77,
175.08,174.40,80.88,80.82,50.32,49.26,42.51,41.35,27.96,27.88,23.35,21.84,
15.16,14.44,11.93,11.22;HRMS(ESI‑):calcd for C11H19O4‑[M‑H]‑215.1289,found
215.1286.
13
1.39–1.22(m,3H),0.93–0.88(m,3H);C NMR(101MHz,CDCl3)δ181.07,180.39,174.63,
174.08,80.86,48.25,47.48,42.65,41.66,32.14,30.80,27.93,27.85,20.66,20.15,
15.07,14.31,13.98,13.82;HRMS(ESI‑):calcd for C12H21O4‑[M‑H]‑229.1445,found
229.1450.
13
1.74(m,1H),1.44(s,1.5H),1.41(s,7.5H),1.17(d,J=8.0Hz,3H);C NMR(101MHz,CDCl3)
δ180.72,180.03,174.28,173.78,141.29,141.14,128.63,128.55,128.41,128.38,
126.12,126.02,82.11,81.00,47.76,47.11,42.60,41.64,33.67,33.28,31.59,30.40,
27.88,27.54,14.89,14.09;HRMS(ESI‑):calcd for C17H23O4‑[M‑H]‑291.1602,found
291.1606.
2.93(m,2H),2.03–1.82(m,5H),1.64–1.53(m,1H),1.40(s,9H);C NMR(101MHz,CDCl3)δ
180.62,173.02,80.67,77.32,77.00,76.68,47.83,46.75,28.82,28.59,27.85,23.73;
HRMS(ESI‑):calcd for C11H17O4‑[M‑H]‑213.1132,found 213.1137.
13
3H);C NMR(101MHz,CDCl3)δ180.21,174.40,81.29,46.86,27.92,23.66,21.53,12.21;
HRMS(ESI‑):calcd for C11H19O4‑[M‑H]‑215.1289,found 215.1285.
13
10H),1.31–1.23(m,4H),1.15(d,J=8.0Hz,3H);C NMR(101MHz,CDCl3)δ180.84,174.03,
81.15,48.95,48.32,31.50,31.44,27.91,25.61,23.12,23.10,12.38.;HRMS(ESI‑):calcd
for C14H23O4‑[M‑H]‑255.1602,found 255.1603.
(2ea):浅黄色液体;H NMR(400MHz,CDCl3)δ4.64(dd,J=8.0,4.0Hz,1H),2.91–2.73(m,
2H),2.44(ddd,J=20.0,8.0,4.0Hz,1H),1.82–1.66(m,4H),1.57–1.51(m,1H),1.24–1.21
13
(m,3H),1.15–1.04(m,2H),0.96(d,J=4.0Hz,3H),0.83(s,6H);C NMR(101MHz,CDCl3)δ
177.76,174.47,174.43,81.46,81.45,48.70,48.67,46.90,46.88,44.98,38.68,38.67,
37.26,35.89,35.81,33.72,27.00,26.99,20.07,19.85,19.83,16.98,16.92,11.34,
11.32;HRMS(ESI‑):calcd for C15H23O4‑[M‑H]‑267.1602,found 267.1602.
浅黄色液体;H NMR(400MHz,CDCl3)δ4.71–4.63(m,1H),2.91–2.74(m,2H),2.46–2.40(m,
1H),2.01–1.84(m,2H),1.69–1.65(m,2H),1.49–1.36(m,2H),1.24–1.21(m,3H),1.09–0.93
13
(m,3H),0.90–0.87(m,6H),0.73(d,J=8.0Hz,3H);C NMR(101MHz,CDCl3)δ177.60,
177.53,174.78,174.73,74.59,74.46,46.98,46.96,40.65,40.64,37.43,37.33,35.94,
35.89,34.24,31.35,31.34,26.15,26.06,23.38,23.21,22.00,21.99,20.79,20.69,
17.08,17.01,16.15,16.00;HRMS(ESI‑):calcd for C15H25O4‑[M‑H]‑269.1758,found
269.1754.
液体;H NMR(400MHz,CDCl3)δ6.35(s,1H),5.23(s,1H),2.87–2.63(m,3H),2.46–2.27(m,
3H),2.15–2.11(m,1H),2.01–1.84(m,2H),1.70–1.57(m,4H),1.16(dd,J=8.0,4.0Hz,3H),
13
0.89–0.86(m,6H);C NMR(101MHz,CDCl3)δ177.70,177.67,174.95,174.93,133.58,
133.42,117.57,117.50,86.54,86.48,37.92,37.04,32.40,29.83,29.80,27.75,27.58,
27.40,27.26,23.08,23.05,17.62,17.45,17.22,17.20,17.07,16.87;HRMS(ESI‑):calcd
for C15H23O4‑[M‑H]‑267.1602,found 267.1598.
体;H NMR(400MHz,CDCl3)δ6.22(s,1H),5.36(s,1H),2.84–2.64(m,2H),2.36(dd,J=16.0,
8.0Hz,1H),2.02–1.92(m,4H),1.85–1.77(m,2H),1.63(s,3H),1.41(dd,J=8.0,4.0Hz,
13
6H),1.34–1.28(m,1H),1.18(d,J=8.0Hz,3H);C NMR(101MHz,CDCl3)δ177.63,174.69,
133.95,133.89,120.31,120.25,85.30,42.91,42.87,37.96,36.98,36.96,30.85,26.30,
26.27,23.85,23.82,23.29,23.22,23.14,23.06,22.98,17.12;HRMS(ESI‑):calcd for
C15H23O4‑[M‑H]‑267.1602,found 267.1596.
8.0Hz,1H),2.31–2.28(m,2H),2.02–1.94(m,2H),1.86–1.78(m,3H),1.58–1.34(m,10H),
1.23(d,J=4.0Hz,3H),1.15–1.05(m,7H),1.04–0.95(m,4H),1.01(s,3H),0.91(d,J=
13
8.0Hz,3H),0.86(dd,J=8.0,4.0Hz,6H),0.67(s,3H);C NMR(101MHz,CDCl3)δ177.69,
177.68,174.54,174.51,139.53,139.50,122.68,122.66,74.31,56.66,56.12,49.98,
39.71,39.49,37.90,37.36,36.93,36.55,36.16,35.78,31.88,31.83,28.21,27.99,
27.59,27.58,24.27,23.82,22.81,22.55,21.02,19.30,18.70,16.99,11.84;HRMS(ESI‑):
calcd for C32H51O4‑[M‑H]‑499.3793,found 499.3794.
量分数为0.4~0.5%。
2H),7.23–7.19(m,3H),2.96(t,J=8.0Hz,2H),2.68(t,J=8.0Hz,2H);C NMR(101MHz,
CDCl3)δ179.37,140.16,128.59,128.28,126.40,35.65,30.59;MS(ESI‑):149.09.
(s,4H),2.93(t,J=8.0Hz,2H),2.67(t,J=8.0Hz,2H),2.33(s,3H);C NMR(101MHz,
CDCl3)δ178.99,137.04,135.86,129.21,128.11,35.70,30.14,21.01;MS(ESI‑):163.11.
13
2H),1.32(s,9H);C NMR(101MHz,CDCl3)δ178.89,149.19,137.06,127.89,125.44,35.50,
34.38,31.36,30.01;MS(ESI‑):263.11.
13
(t,J=8.0Hz,2H);C NMR(101MHz,CDCl3)δ178.56,158.12,132.21,129.21,113.95,
55.25,35.80,29.74;MS(ESI‑):179.01.
13
;C NMR(101MHz,CDCl3)δ178.57,161.52(d,J=245.4Hz),135.73(d,J=3.0Hz),129.69
19
(d,J=8.1Hz),115.32(d,J=22.2Hz),35.63,29.75;F NMR(376MHz,CDCl3)δ‑116.83;MS
(ESI‑):167.09.
13
2.68(t,J=8.0Hz,2H);C NMR(101MHz,CDCl3)δ178.42,147.84,146.14,134.53,129.15,
‑ ‑
129.04,124.42,123.94,122.52,35.53,29.96;HRMS(ESI‑):calcd for C12H13O3 [M‑H]
316.1343,found 316.1345.
13
2H),2.99(t,J=8.0Hz,2H),2.71(t,J=8.0Hz,2H);C NMR(101MHz,CDCl3)δ177.62,
142.05,139.07,134.08,128.72,126.61,126.27,126.16,119.99,35.28,30.26.MS(ESI‑):
230.91.
7.16–7.13(m,4H),2.96(t,J=8.0Hz,2H),2.65(t,J=8.0Hz,2H),2.33(s,3H);C NMR
(101MHz,CDCl3)δ178.02,138.23,135.95,130.34,128.41,126.52,126.17,34.11,27.98,
19.23;MS(ESI‑):163.01.
13
8.0Hz,2H);C NMR(101MHz,CDCl3)δ179.24,157.44,129.92,128.45,127.69,120.42,
110.17,55.13,33.87,25.87;MS(ESI‑):179.01.
7.18(m,2H),7.09–7.00(m,2H),2.99(t,J=8.0Hz,2H),2.70(t,J=8.0Hz,2H);C NMR
(101MHz,CDCl3)δ178.68,161.13(d,J=246.4Hz),130.56(d,J=5.0Hz),128.21(d,J=
8.0Hz),126.94(d,J=15.2Hz),124.09(d,J=4.0Hz),115.33(d,J=22.2Hz),34.06(d,J=
19
1.0Hz),24.27(d,J=3.0Hz);F NMR(376MHz,CDCl3)δ‑118.47;MS(ESI‑):167.09.
13
4.0Hz,2H),2.99(t,J=8.0Hz,2H),2.70(t,J=8.0Hz,2H);C NMR(101MHz,CDCl3)δ
179.39,156.42,133.33,130.05,128.75,127.62,120.63,117.00,111.46,68.54,33.93,
‑ ‑
25.95;HRMS(ESI‑):calcd for C12H13O3[M‑H]205.0870,found205.0865.
13
(s,3H);C NMR(101MHz,CDCl3)δ179.13,140.07,138.13,129.04,128.44,127.09,125.21,
35.62,30.50,21.36;MS(ESI‑):163.09.
13
8.0Hz,2H);C NMR(101MHz,CDCl3)δ178.45,159.72,141.75,129.54,120.57,114.06,
111.68,55.15,35.40,30.62;MS(ESI‑):179.07.
7.20(m,1H),6.97–6.87(m,3H),2.94(t,J=8.0Hz,2H),2.67(t,J=8.0Hz,2H);C NMR
(101MHz,CDCl3)δ178.66,162.91(d,J=246.4Hz),142.61(d,J=7.1Hz),130.0(d,J=
8.1Hz),123.89(d,J=2.0Hz),115.20(d,J=21.2Hz),113.30(d,J=21.2Hz),35.21,30.22
19
(d,J=2.0Hz);F NMR(376MHz,CDCl3)δ‑113.33;MS(ESI‑):167.09.All analytical data
7
are consistent with those reported in the literature.
13
J=8.0Hz,1H),6.87–6.84(m,2H),2.93(t,J=8.0Hz,2H),2.66(t,J=8.0Hz,2H);C NMR
(101MHz,CDCl3)δ178.51,157.40,157.08,142.20,129.79,129.72,123.24,123.08,
‑ ‑
118.90,118.69,116.73,35.42,30.46;HRMS(ESI‑):calcd for C11H17O4 [M‑H] 241.0870,
found 241.0868.
13
(d,J=4.0Hz,3H);C NMR(101MHz,CDCl3)δ178.34,160.04(d,J=244.4Hz),135.44(d,J=
4.0Hz),131.25(d,J=5.1Hz),126.87(d,J=8.1Hz),124.74(d,J=17.2Hz),114.91(d,J=
19
22.2Hz),35.64,29.76,14.52(d,J=4.0Hz);F NMR(376MHz,CDCl3)δ‑121.25;HRMS
‑ ‑
(ESI‑):calcd for C11H17O4[M‑H]181.0670,found 181.0673.
13
2.23(d,J=4.0Hz,3H);C NMR(101MHz,CDCl3)δ177.67,161.25(d,J=245.4Hz),139,72
(d,J=8.1Hz),131.43(d,J=6.1Hz),123.55(d,J=3.0Hz),122.65(d,J=17.2Hz),114.79
19
(d,J=22.2Hz),35.19,29.94(d,J=2.0Hz),14.15(d,J=3.0Hz);F NMR(376MHz,CDCl3)
‑ ‑
δ‑117.66;HRMS(ESI‑):calcd for C11H17O4[M‑H]181.0670,found 181.0674.
13
2.63(t,J=8.0Hz,2H);C NMR(101MHz,CDCl3)δ178.30,157.26,152.94(d,J=247.4Hz),
143.48(d,J=12.1Hz),136.88(d,J=4.0Hz),129.69,124.36(d,J=6.1Hz),123.12,
19
121.62(d,J=2.0Hz),117.25,116.98(d,J=19.2Hz),35.40,29.8;F NMR(376MHz,CDCl3)
‑ ‑
δ‑134.15;HRMS(ESI‑):calcd for C11H17O4[M‑H]259.0776,found 259.0776.
13
(s,6H);C NMR(101MHz,CDCl3)δ178.57,136.00,135.75,135.16,131.15,128.38,126.78,
34.38,27.61,20.89,19.15;MS(ESI‑):177.09.
13
(s,3H);C NMR(101MHz,CDCl3)δ178.37,161.38(d,J=244.4Hz),138.14(d,J=8.1Hz),
133.81(d,J=3.0Hz),129.80(d,J=8.1Hz),116.93(d,J=21.2Hz),112.69(d,J=
19
21.2Hz),34.30,27.25,19.35(d,J=2.0Hz);F NMR(376MHz,CDCl3)δ‑117.31;MS(ESI‑):
181.07.
13
J=8.0Hz,2H);C NMR(101MHz,CDCl3)δ178.81,161.52(d,J=246.4Hz),159.52(d,J=
11.1Hz),130.77(d,J=7.1Hz),118.77(d,J=6.1Hz),109.66(d,J=3.0Hz),101.65(d,J=
19
25.2Hz),55.5,34.46(d,J=1.0Hz),23.73(d,J=2.0Hz);F NMR(376MHz,CDCl3)δ‑
116.33;MS(ESI‑):197.06.
13
4.0Hz,1H),3.80(s,3H),3.04(t,J=8.0Hz,2H),2.61(t,J=8.0Hz,2H);C NMR(101MHz,
CDCl3)δ178.71,157.84,132.18,130.64(d,J=1.0Hz),129.40(q,J=30.3Hz),124.22(q,J
=275.7Hz),117.23(d,J=1.0Hz),111.83(q,J=6.1Hz),55.43,36.16,26.89(d,J=
19 ‑ ‑
1.0Hz);F NMR(376MHz,CDCl3)δ‑60.12;HRMS(ESI‑):calcd for C11H17O4 [M‑H]
247.0588,found 247.0584.
13
(s,6H);C NMR(101MHz,CDCl3)δ179.27,135.49,134.53,134.07,133.04,131.73,129.89,
‑ ‑
34.65,27.60,19.19,19.13,18.57;HRMS(ESI‑):calcd for C11H17O4 [M‑H]191.1078,
found 191.1077.
13
(t,J=8.0Hz,2H),2.48–2.46(m,2H);C NMR(101MHz,DMSO‑d6)δ173.74,140.15,139.18,
‑ ‑
127.90,126.52,62.74,35.35,30.05;HRMS(ESI‑):calcd for C11H17O4 [M‑H] 179.0714,
found 179.0715.
13
2H),2.79(t,J=8.0Hz,2H);C NMR(101MHz,CDCl3)δ178.85,137.60,133.54,132.16,
128.18,127.60,127.50,126.85,126.44,126.05,125.43,35.47,30.72;MS(ESI‑):199.08.
8.0,1H),6.51(d,J=4.0Hz,1H),3.05(t,J=8.0Hz,2H),2.72(t,J=8.0Hz,2H),1.66(s,
13
9H);C NMR(101MHz,CDCl3)δ178.61,149.75,134.51,130.84,126.17,124.65,120.25,
115.13,107.08,83.61,36.10,30.54,28.18;MS(ESI‑):288.10.
7.16(m,10H),4.51(t,J=8.0Hz,1H),3.07(d,J=8.0Hz,2H);C NMR(101MHz,CDCl3)δ
177.39,143.21,128.60,127.59,126.61,46.59,40.35;MS(ESI‑):225.09.
13
8.0Hz,2H),4.47(t,J=8.0Hz,1H),3.76(s,3H),3.05(t,J=8.0Hz,2H);C NMR(101MHz,
CDCl3)δ177.66,158.13,143.72,135.48,128.56,127.50,126.45,113.94,55.17,45.90,
40.85;MS(ESI‑):255.10.
13
3.05(dd,J=8.0,2.0Hz,2H);C NMR(101MHz,CDCl3)δ177.52,161.53(d,J=246.4Hz),
142.99,138.92,129.08(d,J=8.1Hz),128.69,127.46,126.76,115.42(d,J=22.2Hz),
19
45.86,40.49;F NMR(376MHz,CDCl3)δ‑116.29;MS(ESI‑):243.09.
13
(d,J=8.0Hz,2H),4.42(t,J=8.0Hz,1H),3.75(s,3H),2.96(d,J=8.0Hz,2H);C NMR
(101MHz,CDCl3)δ177.29,161.43(d,J=245.4Hz),158.24,139.45(d,J=3.0Hz),135.27,
19
128.98(d,J=8.1Hz),128.45,115.33(d,J=21.2Hz),114.02,55.19,45.22,41.01;F NMR
‑ ‑
(376MHz,CDCl3)δ‑116.52;HRMS(ESI‑):calcd for C11H17O4 [M‑H] 273.0932,
found273.0933.
δ7.18–7.14(m,4H),6.99–6.95(m,4H),4.49(t,J=8.0Hz,1H),3.03(d,J=8.0Hz,2H);C
NMR(101MHz,CDCl3)δ176.71,161.59(d,J=246.4Hz),138.72(d,J=4.0Hz),128.99(d,J=
19
8.1Hz),115.53(d,J=21.2Hz),45.18,40.56;F NMR(376MHz,CDCl3)δ‑116.02;MS(ESI‑):
261.08.
13
6H),2.99(d,J=8.0Hz,2H);C NMR(101MHz,CDCl3)δ177.63,158.07,135.85,128.45,
113.91,55.17,45.09,41.01;MS(ESI‑):285.03.
13
(t,J=8.0Hz,2H),3.01(d,J=8.0Hz,2H),1.81–1.72(s,2H),1.00(d,J=8.0Hz,3H);C
NMR(101MHz,CDCl3)δ177.41,157.71,143.77,135.26,128.53,127.51,126.43,114.49,
‑ ‑
69.40,45.92,40.83,22.57,10.52.HRMS(ESI‑):calcd for C18H19O3 [M‑H] 283.1340,
found 283.1341.
7.18(m,3H),3.30–3.21(m,1H),2.68–2.52(m,2H),1.31(d,J=8.0Hz,3H);C NMR(101MHz,
CDCl3)δ178.41,145.52,128.52,126.68,126.44,42.73,36.19,21.82.MS(ESI‑):163.10.
13
(m,2H);C NMR(101MHz,CDCl3)δ178.35,143.10,139.27,129.18,128.39,128.19,127.43,
126.63,126.19,43.55,42.95,39.75;MS(ESI‑):239.01.
13
1.93(m,1H),1.90–1.73(m,3H);C NMR(101MHz,CDCl3)δ179.08,138.98,137.13,129.28,
128.19,126.07,125.87,41.90,34.36,29.47,28.03,19.46;MS(ESI‑):188.96.
7.31‑7.13(m,10H),4.06(d,J=12.0Hz,1H),3.34(m,1H),1.14(d,J=8.0Hz,3H);C NMR
(101MHz,CDCl3)δ180.17,142.86,142.03,128.68,128.52,128.14,127.52,126.64,
‑ ‑
126.54,54.68,44.06,17.13.HRMS(ESI‑):calcd for C16H15O2 [M‑H] 239.1078,found
239.1086.
即可作出的各种修改和变形仍属本专利的保护范围。